| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f07ba5e7ff356b7eda43fdfc20eef4b0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16322 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2026
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-204
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-162
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-208
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-21 |
| filingDate |
2005-03-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2008-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44dae813ecefa93732d9a006c1e350ad
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_54ad2728eacb56cb8ad44bc22facf95e |
| publicationDate |
2008-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7335365-B2 |
| titleOfInvention |
HIV-encoded chemoattractant |
| abstract |
The combination of HIV proteins Tat and Nef is chemotactic for CD4+ cells. Utilizing the capacity of Tat and Nef to modulate CD4+ cell trafficking and infiltration, the invention provides various treatment modes for individuals infected with HIV. The invention further provides treatment modes for other localized diseases by controlling CD4+ cell trafficking and infiltration. In particular, the invention provides methodology for promoting CD4+ cell chemotaxis to a localized site of infection as a means of augmenting the efficacy of extant chemotherapeutic methods. The invention further provides methodology for diverting CD4+ cell infiltration from a localized site where the presence of CD4+ cells is detrimental to the clinical outcome, by providing a composition comprising Tat and Nef at a distinct site, such as blood, within the individual where the accumulation of CD4+ cells is less detrimental. |
| priorityDate |
1999-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |